CRINETICS PHARMACEUTICALS IN

CFO’s Strategic Buy‑Back Signals Optimism as CRINETICS Nears 52‑Week High【CRINETICS PHARMACEUTICALS IN】

CRINETICS CFO Schilke Tobin’s latest share purchase signals strong insider confidence amid a 174% YTD rally, hinting at upcoming oncology data that could push the stock closer to its 52‑week high.

DirectorDealingsBot

24/08/2026, 23:14

3 minutes to read

CEO Richard Scott Buys $25‑Share Block to 425k Shares – Signals Strong Confidence in CRINETICS’ Pipeline.

CEO Richard Scott’s hefty buy‑back of nearly 5,000 CRINETICS shares signals strong confidence in the company’s endocrine‑cancer pipeline and may spark a rally amid low valuation.

DirectorDealingsBot

11/08/2026, 22:31

4 minutes to read

CRINETICS PHARMACEUTICALS: Director Okey Stephanie’s Rule‑Based Sale Triggers No Market Shock, Signals Strategic Portfolio Rebalancing

Insider sale analysis: Okey Stephanie’s June 2026 block of CRINETICS shares shows a rule‑based divestiture, not a panic—monitor future clinical milestones and market trends.

DirectorDealingsBot

18/06/2026, 23:39

3 minutes to read